Reports
Sale
Cardiometabolic Disease Market Size, Share, Growth, Trends: By Disease Type: Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity, Others; By Treatment Type: ACE Inhibitors, Diuretics, Glucophage, Others; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Cardiometabolic Disease Market Outlook
The cardiometabolic disease market size was valued at USD 34.1 billion in 2023, driven by the rising incidence of risk factors such as sedentary lifestyle, obesity, and aging population across the 8 major markets. The market is expected to grow at a CAGR of 5.4% during the forecast period of 2024-2032, with the values likely to rise from USD 36 billion in 2024 to USD 54.8 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiometabolic Disease Market Overview
Cardiometabolic illnesses are a group of metabolic diseases that can increase the risk of cardiovascular disease in people. These conditions include heart attack, stroke, insulin resistance, diabetes, and non-alcoholic fatty liver disease. The number of people experiencing one or more of these chronic preventable conditions is rising driven by factors such as smoking, unhealthy dietary habits, sedentary lifestyle, and excessive alcohol consumption.
The increasing incidence of risk factors is contributing to the growing prevalence of cardiometabolic diseases, which is expected to directly impact the cardiometabolic disease market demand. In the United States, a significant portion of the population is affected by these conditions. It is estimated that 11% of adults in the region are diagnosed with diabetes and around 10% are diagnosed with cardiovascular diseases such as stroke, coronary heart disease, and heart failure. The rising burden of these cardiometabolic conditions is likely to influence the demand for effective treatment solutions and advanced diagnostic methods.
The cardiometabolic disease market growth is driven by increased merger and acquisition initiatives among the key market players in order to share resources and expertise and accelerate the development of life-saving treatments for cardiometabolic diseases. In July 2023, Eli Lilly and Company announced that they had signed a definitive agreement to acquire Versanis Bio (a United States-based clinical-stage biopharmaceutical company) in a deal worth USD 1.925 billion to develop new therapeutics for the treatment of cardiometabolic diseases and improve patient outcomes. Versanis’ lead candidate bimagrumab has the potential to reduce fat mass without affecting muscle mass and is undergoing clinical trials in overweight and obese patients. This partnership aims to leverage Versanis’ expertise in activin biology and Lilly’s knowledge of incretin biology to create new medicines to combat cardiometabolic diseases. The rise in such strategic partnerships is expected to fuel market growth in the coming years.
One of the significant cardiometabolic disease market trends is the advancement in medical technology such as the rise in AI-driven drug development. In September 2023, Novo Nordisk A/S struck a deal worth USD 60 million and milestone payment amounting to USD 2.7 billion with a health technology company in the United States, Valo Health, to develop new treatments for cardiometabolic diseases by leveraging artificial intelligence. Under the agreement, the companies intend to utilize Valo’s Opal Computational Platform (for accessing real-world patient data), AI-enabled small molecule discovery, and the Biowire platform (to make heart tissue out of human cardiac cell samples). This indicates the growing adoption of artificial intelligence and machine learning platforms which are likely to boost the market value in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiometabolic Disease Market Segmentation
Market Breakup by Disease Type
- Chronic/Congestive Heart Failure
- Hypertension
- Type 2 Diabetes
- Obesity
- Others
By disease type, the cardiometabolic disease market includes chronic/congestive heart failure, hypertension, type 2 diabetes, obesity, and other cardiometabolic conditions. This market segment covers a range of disorders affecting the cardiovascular and metabolic health.
Market Breakup by Treatment Type
- ACE Inhibitors
- Diuretics
- Glucophage
- Liposuction
- Others
In terms of treatment type, options include ACE inhibitors, diuretics, glucophage, liposuction, and other medications or interventions to manage cardiometabolic diseases.
Market Breakup by Route of Administration
- Oral
- Intravenous
- Others
By route of administration, the market comprises oral, intravenous, and other routes.
Market Breakup by End User
- Hospitals
- Clinics
- Homecare Settings
- Others
In terms of end users, the cardiometabolic disease market share includes hospitals, clinics, homecare settings, and other healthcare facilities where patients receive care for these conditions.
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Distribution channels for cardiometabolic disease treatments include hospital pharmacies, retail pharmacies, online pharmacies, and others. This segment offers patients access to medications through a robust network of distribution channels.
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America is leading the market share, which can be attributed to the growing investment in research and development activities, high healthcare expenditure, and a well-developed healthcare sector in the region. Furthermore, the growing demand for advanced and innovative treatments to manage cardiometabolic diseases is likely to fuel the market in the coming years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cardiometabolic Disease Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- biocrates life sciences ag
- Eli Lilly and Company
- Alnylam Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc.
- Dicerna Pharmaceuticals, Inc.
- Cardax, Inc.
- Novartis AG
- Novo Nordisk A/S
- Boehringer Ingelheim International GmbH
- Kowa Company, Ltd
- Allergan
- AstraZeneca
- Pfizer Inc.
- Merck & Co., Inc.
- Sanofi SA
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Queries Solved in the Cardiometabolic Disease Market Report
- How has the market performed so far and how will it perform in the coming years?
- What are the major trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of cardiometabolic diseases affect the market landscape?
- How does the rise in the geriatric population impact the cardiometabolic disease market size?
- Which disease type will significantly influence the market growth?
- Which treatment type is expected to dominate the market share?
- Which distribution channel is expected to have a high market value in the coming years?
- Which end user is poised to lead the market share?
- How will the ongoing clinical trials impact the market value during the forecast period?
- What are the factors driving regional disparities in the treatment and outcomes of cardiometabolic diseases?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, along with mergers and acquisitions among the key market players shaping the market dynamics?
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cardiometabolic Disease Market Overview – 8 Major Markets
3.1 Cardiometabolic Disease Market Historical Value (2017-2023)
3.2 Cardiometabolic Disease Market Forecast Value (2024-2032)
4 Cardiometabolic Disease Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Cardiometabolic Disease Epidemiology Scenario and Forecast – 8 Major Markets
6.1 8MM Epidemiology Scenario Overview (2017-2032)
6.2 United States Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3 EU-4 and United Kingdom Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3.1 Germany Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3.2 France Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3.3 Italy Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3.4 Spain Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.3.5 United Kingdom Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.4 Japan Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
6.5 India Cardiometabolic Disease Epidemiology Scenario and Forecast (2017-2032)
7 Cardiometabolic Disease Market Landscape – 8 Major Markets
7.1 Cardiometabolic Disease: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Cardiometabolic Disease: Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Cardiometabolic Disease Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Cardiometabolic Disease Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Cardiometabolic Disease Market Segmentation (2017-2032) - 8 Major Markets
11.1 Cardiometabolic Disease Market (2017-2032) by Disease Type
11.1.1 Market Overview
11.1.2 Chronic/Congestive Heart Failure
11.1.3 Hypertension
11.1.4 Type 2 Diabetes
11.1.5 Obesity
11.1.6 Others
11.2 Cardiometabolic Disease Market (2017-2032) by Treatment Type
11.2.1 Market Overview
11.2.2 ACE Inhibitors
11.2.3 Diuretics
11.2.4 Glucophage
11.2.5 Liposuction
11.2.6 Others
11.3 Cardiometabolic Disease Market (2017-2032) by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Intravenous
11.3.4 Others
11.4 Cardiometabolic Disease Market (2017-2032) by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Homecare Settings
11.4.5 Others
11.5 Cardiometabolic Disease Market (2017-2032) by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Cardiometabolic Disease Market (2017-2032) by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
11.6.5 India
12 United States Cardiometabolic Disease Market (2017-2032)
12.1 United States Cardiometabolic Disease Market Historical Value (2017-2023)
12.2 United States Cardiometabolic Disease Market Forecast Value (2024-2032)
12.3 United States Cardiometabolic Disease Market (2017-2032) by Disease Type
12.3.1 Market Overview
12.3.2 Chronic/Congestive Heart Failure
12.3.3 Hypertension
12.3.4 Type 2 Diabetes
12.3.5 Obesity
12.3.6 Others
12.4 United States Cardiometabolic Disease Market (2017-2032) by Treatment Type
12.4.1 Market Overview
12.4.2 ACE Inhibitors
12.4.3 Diuretics
12.4.4 Glucophage
12.4.5 Liposuction Others
12.4.6 Others
13 EU-4 and United Kingdom Cardiometabolic Disease Market (2017-2032)
13.1 EU-4 and United Kingdom Cardiometabolic Disease Market Historical Value (2017-2023)
13.2 EU-4 and United Kingdom Cardiometabolic Disease Market Forecast Value (2024-2032)
13.3 EU-4 and United Kingdom Cardiometabolic Disease Market (2017-2032) by Disease Type
13.3.1 Market Overview
13.3.2 Chronic/Congestive Heart Failure
13.3.3 Hypertension
13.3.4 Type 2 Diabetes
13.3.5 Obesity
13.3.6 Others
13.4 EU-4 and United Kingdom Cardiometabolic Disease Market (2017-2032) by Treatment Type
13.4.1 Market Overview
13.4.2 Market Overview
13.4.3 ACE Inhibitors
13.4.4 Diuretics
13.4.5 Glucophage
13.4.6 Liposuction Others
13.4.7 Others
14 Japan Cardiometabolic Disease Market
14.1 Japan Cardiometabolic Disease Market Historical Value (2017-2023)
14.2 Japan Cardiometabolic Disease Market Forecast Value (2024-2032)
14.3 Japan Cardiometabolic Disease Market (2017-2032) by Disease Type
14.3.1 Market Overview
14.3.2 Chronic/Congestive Heart Failure
14.3.3 Hypertension
14.3.4 Type 2 Diabetes
14.3.5 Obesity
14.3.6 Others
14.4 Japan Cardiometabolic Disease Market (2017-2032) by Treatment Type
14.4.1 Market Overview
14.4.2 Market Overview
14.4.3 ACE Inhibitors
14.4.4 Diuretics
14.4.5 Glucophage
14.4.6 Liposuction Others
14.4.7 Others
15 India Cardiometabolic Disease Market
15.1 India Cardiometabolic Disease Market (2017-2032) Historical Value (2017-2023)
15.2 India Cardiometabolic Disease Market (2017-2032) Forecast Value (2024-2032)
15.3 India Cardiometabolic Disease Market (2017-2032) by Disease Type
15.3.1 Market Overview
15.3.2 Chronic/Congestive Heart Failure
15.3.3 Hypertension
15.3.4 Type 2 Diabetes
15.3.5 Obesity
15.3.6 Others
15.4 India Cardiometabolic Disease Market (2017-2032) by Treatment Type
15.4.1 Market Overview
15.4.2 Market Overview
15.4.3 ACE Inhibitors
15.4.4 Diuretics
15.4.5 Glucophage
15.4.6 Liposuction Others
15.4.7 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 Japan PMDA
16.1.4 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication Year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by Year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 biocrates life sciences ag
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisition
22.2.5 Certifications
22.3 Eli Lilly and Company
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisition
22.3.5 Certifications
22.4 Alnylam Pharmaceuticals, Inc.
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisition
22.4.5 Certifications
22.5 Arrowhead Pharmaceuticals, Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisition
22.5.5 Certifications
22.6 Dicerna Pharmaceuticals, Inc.
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisition
22.6.5 Certifications
22.7 Cardax, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisition
22.7.5 Certifications
22.8 Novartis AG
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisition
22.8.5 Certifications
22.9 Novo Nordisk A/S
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisition
22.9.5 Certifications
22.10 Boehringer Ingelheim International GmbH
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisition
22.10.5 Certifications
22.11 Kowa Company, Ltd
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisition
22.11.5 Certifications
22.12 Allergan
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisition
22.12.5 Certifications
22.13 AstraZeneca
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisition
22.13.5 Certifications
22.14 Pfizer Inc.
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisition
22.14.5 Certifications
22.15 Merck & Co., Inc.
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisition
22.15.5 Certifications
22.16 Sanofi SA
22.16.1 Financial Analysis
22.16.2 Product Portfolio
22.16.3 Demographic Reach and Achievements
22.16.4 Mergers and Acquisition
22.16.5 Certifications
23 Cardiometabolic Disease Treatment Drugs - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 34.1 billion in 2023 driven by the rising incidence of risk factors such as sedentary lifestyle, obesity, and aging population across the 8 major markets.
The market is anticipated to grow at a CAGR of 5.4% during the forecast period of 2024-2032, likely to reach a market value of USD 54.8 billion by 2032.
The market demand is driven by the growing prevalence of cardiometabolic diseases and the rising advancements in medical technology.
One of the significant trends in the market is the increased merger and acquisition initiatives among the key market players. In July 2023 , Eli Lilly and Company signed a definitive agreement to acquire Versanis Bio in a deal worth USD 1.925 billion to develop new therapeutics to manage cardiometabolic diseases.
Based on the disease type, the market includes chronic/congestive heart failure, hypertension, type 2 diabetes, obesity, and other cardiometabolic conditions.
Based on the treatment type, the market is segmented into ACE inhibitors, diuretics, glucophage, liposuction, and other medications.
By route of administration, the market comprises oral, intravenous, and other routes.
Major end users of the market are hospitals, clinics, homecare settings, and other healthcare facilities.
Distribution channels in the market include hospital pharmacies, retail pharmacies, online pharmacies, and others.
The major regions of the market include the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India.
Key players involved in the market are biocrates life sciences ag, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Cardax, Inc., Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Kowa Company, Ltd., Allergan, AstraZeneca, Pfizer Inc., Merck & Co., Inc., and Sanofi SA.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER